




Instance: composition-en-6f21bde7c462d7396cfc7185d72d2377
InstanceOf: CompositionUvEpi
Title: "Composition for locametz Package Leaflet"
Description:  "Composition for locametz Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/22/1692/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6f21bde7c462d7396cfc7185d72d2377)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - locametz"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  
  </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol type="1">
<li>What Locametz is and what it is used for</li>
<li>What you need to know before Locametz is used</li>
<li>How Locametz is used</li>
<li>Possible side effects</li>
<li>How Locametz is stored</li>
<li>Contents of the pack and other information</li>
</ol>
 </div>"""   
          

* section[=].section[+]
  * title =  "1. What locametz is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What locametz is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Locametz is This medicine is a radiopharmaceutical product for
diagnostic use only.</p>
<p>Locametz contains a substance called gozetotide. Before use,
gozetotide (the powder in the vial) is coupled with a radioactive
substance called gallium-68 to make gallium (68Ga) gozetotide solution
(this procedure is called radiolabelling).</p>
<p>What Locametz is used for After radiolabelling with gallium-68,
Locametz is used in a medical imaging procedure called positron emission
tomography (PET) to detect specific types of cancer cells with a protein
called prostate-specific membrane antigen (PSMA) in adults with prostate
cancer. This is done:</p>
<ul>
<li>to find out whether prostate cancer has spread to lymph nodes and
other tissues outside the prostate, before primary curative therapy
(e.g. therapy involving surgical removal of the prostate, radiation
therapy)</li>
<li>to identify cancer cells when recurrence of prostate cancer is
suspected in patients who have received primary curative therapy</li>
<li>to find out whether patients with progressive metastatic
castration-resistant prostate cancer may be suitable for a specific
therapy, called PSMA-targeted therapy</li>
</ul>
<p>How Locametz works When given to the patient, gallium (68Ga)
gozetotide binds to the cancer cells that have PSMA on their surface and
makes them visible to your nuclear medicine doctor during the PET
medical imaging procedure. This gives your doctor and nuclear medicine
doctor valuable information about your disease.</p>
<p>The use of gallium (68Ga) gozetotide involves exposure to a small
amount of radioactivity. Your doctor and the nuclear medicine doctor
have considered that the clinical benefit that you will obtain from the
procedure with the radiopharmaceutical outweighs the risk due to
radiation.</p>
<p>If you have any questions about how Locametz works or why this
medicine has been prescribed for you, ask your nuclear medicine
doctor.</p>
 </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take locametz"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take locametz"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Locametz must not be used</p>
<ul>
<li>if you are allergic to gozetotide or any of the other ingredients of
this medicine (listed in section 6).</li>
</ul>
<p>Warnings and precautions Talk to your nuclear medicine doctor before
you receive Locametz if you have any other type of cancer, as this could
affect the interpretation of the image.</p>
<p>The use of Locametz involves exposure to a small amount of
radioactivity. Repeated exposure to radiation may increase the risk of
cancer. Your nuclear medicine doctor will explain necessary
radioprotection measures to you (see section 3).</p>
<p>Before administration of Locametz you should</p>
<ul>
<li>Drink plenty of water so that you remain hydrated and urinate
immediately before the PET medical imaging procedure, and as often as
possible during the first hours after administration.</li>
</ul>
<p>Children and adolescents This medicine should not be given to
children or adolescents aged under 18 years because no data are
available in this age group.</p>
<p>Pregnancy and breast-feeding Locametz is not intended for use in
women. All radiopharmaceuticals, including Locametz, have the potential
to cause harm to an unborn baby.</p>
<p>Driving and using machines It is considered unlikely that Locametz
will affect your ability to drive or to use machines.</p>
<p>Locametz contains sodium This medicine contains 28.97 mg sodium (main
component of cooking/table salt) in each injection. This is equivalent
to 1.5% of the recommended maximum daily dietary intake of sodium for an
adult.</p>
 </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take locametz"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take locametz"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>There are strict laws on the use, handling and disposal of
radiopharmaceutical products. Locametz will only be used in special
controlled areas. This radiopharmaceutical product will only be handled
and given to you by people who are trained and qualified to use it
safely. These persons will take special care for the safe use of this
radiopharmaceutical product and will keep you informed of their
actions.</p>
<p>The nuclear medicine doctor supervising the procedure will decide on
the quantity of Locametz to be used in your case. It will be the
smallest quantity necessary to get the desired information.</p>
<p>The quantity to be administered usually recommended for an adult is
1.8-2.2 MBq (megabecquerel, the unit used to express radioactivity) per
kg of body weight, with a minimum amount of 111 MBq and a maximum of 259
MBq.</p>
<p>Administration of Locametz and conduct of the procedure After
reconstitution and radiolabelling, Locametz is given as a slow injection
into a vein. You will undergo a PET scan starting 50 to 100 minutes
after you have received Locametz.</p>
<p>Duration of the procedure Your nuclear medicine doctor will inform
you about the usual duration of the procedure.</p>
<p>After administration of Locametz, you should</p>
<ul>
<li>Continue to drink plenty of water so that you remain hydrated and
urinate as often as possible to eliminate the radiopharmaceutical
product from your body.</li>
</ul>
<p>The nuclear medicine doctor will inform you if you need to take any
special precautions after receiving this medicine. Contact your nuclear
medicine doctor if you have any questions.</p>
<p>If you have been given more Locametz than you should An overdose of
Locametz is unlikely because you will only receive a single dose that is
precisely controlled by the nuclear medicine doctor supervising the
procedure. However, in the event of an overdose, you will receive the
appropriate treatment. You may be asked to drink and urinate frequently
in order to eliminate the radiopharmaceutical product from your
body.</p>
<p>Should you have any further question on the use of Locametz, please
ask the nuclear medicine doctor who supervises the procedure.</p>
 </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</p>
<p>Side effects include the following listed below. If these side
effects become severe, please tell your nuclear medicine doctor.</p>
<p>Common (may affect up to 1 in every 10 people)</p>
<ul>
<li>tiredness (fatigue)</li>
</ul>
<p>Uncommon (may affect up to 1 in every 100 people)</p>
<ul>
<li>nausea</li>
<li>constipation</li>
<li>vomiting</li>
<li>diarrhoea</li>
<li>dry mouth</li>
<li>reactions at the site of injection, such as bruising, itching and
warmth (injection site reactions)</li>
<li>chills</li>
</ul>
<p>This radiopharmaceutical product will deliver low amounts of ionising
radiation associated with the least risk of cancer and hereditary
abnormalities.</p>
<p>Reporting of side effects If you get any side effects, talk to your
nuclear medicine doctor. This includes any possible side effects not
listed in this leaflet. You can also report side effects directly via
the national reporting system listed in Appendix V. By reporting side
effects you can help provide more information on the safety of this
medicine.</p>
 </div>"""      
        
* section[=].section[+]
  * title = "5. How to store locametz"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store locametz"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You will not have to store this medicine. This medicine is stored
under the responsibility of the specialist in appropriate premises.
Storage of radiopharmaceutical products will be in accordance with
national regulations on radioactive materials.</p>
<p>The following information is intended for the specialist only:</p>
<ul>
<li>Locametz must not be used after the expiry date which is stated on
the carton and label after EXP. The expiry date refers to the last day
of that month.</li>
<li>Before reconstitution, store below 25 C.</li>
<li>After reconstitution and radiolabelling, store upright below 30 C.
Use within 6 hours.</li>
</ul>
 </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Locametz contains</p>
<ul>
<li>The active substance is gozetotide. One vial contains 25 micrograms
of gozetotide. The other ingredients are: gentisic acid, sodium acetate
trihydrate and sodium chloride (see Locametz contains sodium in section
2).</li>
</ul>
<p>What Locametz looks like and contents of the pack Locametz is a
multidose kit for radiopharmaceutical preparation containing one vial of
white freeze-dried powder (powder for solution for injection).</p>
<p>Gallium-68 is not part of the kit.</p>
<p>After reconstitution and radiolabelling, Locametz contains a sterile
solution for injection of gallium (68Ga) gozetotide at an activity of up
to 1 369 MBq.</p>
<p>After reconstitution, the gallium (68Ga) gozetotide solution for
injection also contains hydrochloric acid.</p>
<p>Pack size: 1 vial.</p>
<p>Marketing Authorisation Holder Novartis Europharm Limited Vista
Building Elm Park, Merrion Road Dublin 4 Ireland</p>
<p>Manufacturer Advanced Accelerator Applications (Italy) S.R.L. Via
Crescentino snc 13040 Saluggia (VC) Italy</p>
<p>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</p>
<p>Belgi /Belgique/Belgien Novartis Pharma N.V. T l/Tel: +32 2 246 16
Lietuva SAM Nordic vedija Tel: +46 8 720 58<br />
Novartis Bulgaria EOOD : +359 2 489 98 Luxembourg/Luxemburg Novartis
Pharma N.V. T l/Tel: +32 2 246 16 esk republika M.G.P. spol. s r.o. Tel:
+420 602 303 Magyarorsz g Novartis Hung ria Kft. Tel.: +36 1 457 65
Danmark SAM Nordic Sverige Tel: +46 8 720 58 Malta Novartis Pharma
Services Inc. Tel: +356 2122 2Deutschland Novartis Radiopharmaceuticals
GmbH Tel: +49 911 273 0</p>
<p>Nederland Novartis Pharma B.V. Tel: +31 88 04 52 Eesti SAM Nordic
Rootsi Tel: +46 8 720 58 Norge SAM Nordic Sverige Tlf: +46 8 720 58</p>
<p>: +30 22920 63 sterreich Novartis Pharma GmbH Tel: +43 1 86 6Espa a
Advanced Accelerator Applications Ib rica, S.L.U. Tel: +34 97 6600
Polska Advanced Accelerator Applications Polska Sp. z o.o. Tel.: +48 22
275 56 France Advanced Accelerator Applications T l: +33 1 55 47 63
Portugal Novartis Farma - Produtos Farmac uticos, S.A. Tel: +351 21 000
8Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 Rom nia Novartis
Pharma Services Romania SRL Tel: +40 21 31299 Ireland Novartis Ireland
Limited Tel: +353 1 260 12 Slovenija Novartis Pharma Services Inc. Tel:
+386 1 300 75 sland SAM Nordic Sv j<br />
S mi: +46 8 720 58 Slovensk republika Novartis Slovakia s.r.o. Tel: +421
2 5542 5Italia Advanced Accelerator Applications (Italy) S.r.l Tel: +39
0125 561Suomi/Finland SAM Nordic Ruotsi/Sverige Puh/Tel: +46 8 720
58</p>
<p>: +30 22920 63Sverige SAM Nordic Tel: +46 8 720 58 Latvija SAM Nordic
Zviedrija Tel: +46 8 720 58 United Kingdom (Northern Ireland) Novartis
Ireland Limited Tel: +44 1276 698This leaflet was last revised in</p>
<p>Other sources of information</p>
<p>Detailed information on this medicine is available on the European
Medicines Agency web site:</p>
 </div>"""      



Instance: composition-da-6f21bde7c462d7396cfc7185d72d2377
InstanceOf: CompositionUvEpi
Title: "Composition for locametz Package Leaflet"
Description:  "Composition for locametz Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/22/1692/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6f21bde7c462d7396cfc7185d72d2377)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - locametz"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  
  </div>"""   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen</p>
<ol type="1">
<li>Virkning og anvendelse</li>
<li>Det skal du vide, før du får Locametz</li>
<li>Sådan får du Locametz</li>
<li>Bivirkninger</li>
<li>Opbevaring</li>
<li>Pakningsstørrelser og yderligere oplysninger</li>
</ol>
 </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad er Locametz Dette lægemiddel er et radiofarmaceutisk lægemiddel,
der udelukkende anvendes til diagnostisk brug.</p>
<p>Locametz indeholder et stof, der hedder gozetotid. Før brug kobles
gozetotid (pulveret i hætteglasset) sammen med et radioaktivt stof
kaldet gallium-68 for at fremstille gallium (68Ga) gozetotidopløsning
(denne procedure kaldes radioaktiv mærkning).</p>
<p>Sådan anvendes Locametz Efter radioaktiv mærkning med gallium-68
anvendes Locametz i en medicinsk billedundersøgelse kaldet positron
emissions tomografi (PET) for at finde specifikke typer kræftceller med
et protein, som kaldes prostataspecifikt membranantigen (PSMA) hos
voksne med prostatakræft. Dette gøres:</p>
<ul>
<li>for at undersøge hvorvidt prostatakræft har spredt sig til
lymfeknuder og andet væv udenfor prostata, før primær helbredende
behandling (fx behandling, der involverer kirurgisk fjernelse af
prostata, strålebehandling)</li>
<li>for at identificere kræftceller, når der er mistanke om, at
prostatakræften er vendt tilbage hos patienter, der har modtaget primær
helbredende behandling</li>
<li>for at undersøge, hvorvidt patienter med progressiv metastatisk
kastrationsresistent prostatakræft vil være egnede til at modtage en
specifik type behandling, kaldet PSMA- målrettet behandling.</li>
</ul>
<p>Sådan virker Locametz Når det gives til patienten bindes gallium
(68Ga) gozetotid til kræftceller, der har PSMA på overfladen og gør dem
synlige for nuklearmedicineren under en PET-medicinsk
billedundersøgelse. Dette giver lægen og nuklearmedicineren værdifulde
oplysninger om din sygdom.</p>
<p>Anvendelsen af gallium (68Ga) gozetotid indebærer, at du bliver udsat
for en lille mængde radioaktivitet. Din læge og nuklearmedicineren har
vurderet, at den kliniske gavn, du vil få af behandling med et
radiofarmaceutisk lægemiddel, er større end risikoen ved stråling.</p>
<p>Hvis du har spørgsmål til, hvordan Locametz virker, eller hvorfor
dette lægemiddel er blevet ordineret til dig, så tal med
nuklearmedicineren.</p>
 </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  locametz"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  locametz"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Locametz må ikke anvendes</p>
<ul>
<li>hvis du er allergisk over for gozetotid eller et af de øvrige
indholdsstoffer i dette lægemiddel (angivet i punkt 6).</li>
</ul>
<p>Advarsler og forsigtighedsregler Kontakt nuklearmedicineren, før du
får Locametz, hvis du har en anden type kræft, da det kan påvirke
fortolkningen af billedet.</p>
<p>Brugen af Locametz indebærer, at du bliver udsat for en lille mængde
radioaktivitet. Gentagen strålingseksponering kan øge risikoen for
kræft. Nuklearmedicineren vil forklare dig de nødvendige
foranstaltninger til beskyttelse mod stråling (se punkt 3).</p>
<p>Før du får Locametz, skal du</p>
<ul>
<li>Drikke rigeligt med vand for at forblive hydreret og kunne lade
vandet umiddelbart før den PET-medicinske billedundersøgelse, og så ofte
som muligt i de første timer efter.</li>
</ul>
<p>Børn og unge Dette lægemiddel bør ikke gives til børn eller unge
under 18 år, da der ikke foreligger data for denne aldersgruppe.</p>
<p>Graviditet og amning Locametz er ikke beregnet til brug hos kvinder.
Alle radiofarmaceutiske lægemidler, herunder Locametz, kan potentielt
skade et ufødt barn.</p>
<p>Trafik- og arbejdssikkerhed Det anses for usandsynligt, at Locametz
vil påvirke din evne til at føre motorkøretøj eller betjene
maskiner.</p>
<p>Locametz indeholder natrium Dette lægemiddel indeholder 28,97 mg
natrium (hovedkomponent af madlavnings-/bordsalt) pr. injektion. Dette
svarer til 1,5 % af den anbefalede maximale daglige indtagelse af
natrium for en voksen.</p>
 </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage locametz"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage locametz"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Der gælder strenge lovbestemmelser for anvendelse, håndtering og
bortskaffelse af radiofarmaceutiske lægemidler. Locametz vil kun blive
brugt i særlige, kontrollerede områder. Dette radiofarmaceutiske
lægemiddel må kun håndteres og gives til dig af personale, der er oplært
i og kvalificerede til at anvende det på en sikker måde. De pågældende
vil sikre, at det radiofarmaceutiske lægemiddel anvendes på en sikker
måde, og vil holde dig orienteret om, hvad de foretager sig.</p>
<p>Nuklearmedicineren, der overvåger behandlingen, beslutter, hvor stor
en mængde Locametz der skal bruges til netop dig. Det vil være den
mindste mængde, der er nødvendig for at få de ønskede oplysninger.</p>
<p>Den mængde, der normalt skal gives til en voksen, er 1,8-2,2 MBq
(megabecquerel, den enhed, der anvendes til at udtrykke radioaktivitet)
pr. kg legemsvægt, med en minimumsmængde på 111 MBq og en
maksimumsmængde på 259 MBq.</p>
<p>Administration af Locametz og gennemførelse af behandlingen Efter
rekonstitution og radioaktiv mærkning gives Locametz som en langsom
injektion ind i en vene. Du vil få foretaget en PET-scanning, som
starter 50-100 minutter efter, at du har fået Locametz.</p>
<p>Behandlingens varighed Nuklearmedicineren vil fortælle dig om
behandlingens normale varighed.</p>
<p>Efter administration af Locametz, skal du</p>
<ul>
<li>fortsætte med at drikke rigeligt med vand for at forblive hydreret
og kunne lade vandet så ofte som muligt for at fjerne det
radiofarmaceutiske lægemiddel fra kroppen.</li>
</ul>
<p>Nuklearmedicineren vil informere dig om, hvorvidt du skal tage nogen
særlige forholdsregler efter at have fået dette lægemiddel. Kontakt
nuklearmedicineren, hvis du har spørgsmål.</p>
<p>Hvis du har fået for meget Locametz Det er ikke sandsynligt, at du
vil få en Locametz overdosis, da du kun vil få en enkelt dosis, der er
nøjagtigt kontrolleret af nuklearmedicineren, der overvåger
behandlingen. Skulle du alligevel få en overdosis, vil du få den
nødvendige behandling. Du vil måske blive bedt om at drikke og lade
vandet hyppigt for at fjerne det radiofarmaceutiske lægemiddel fra
kroppen.</p>
<p>Hvis du har yderligere spørgsmål om brugen af Locametz, skal du
spørge nuklearmedicineren, der har ansvar for behandlingen.</p>
 </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men
ikke alle får bivirkninger.</p>
<p>Bivirkningerne omfatter dem, der er anført nedenfor. Hvis disse
bivirkninger bliver alvorlige, skal du fortælle det til
nuklearmedicineren.</p>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 patienter)</p>
<ul>
<li>træthed</li>
</ul>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 patienter)</p>
<ul>
<li>kvalme</li>
<li>forstoppelse</li>
<li>opkastning</li>
<li>diarré</li>
<li>mundtørhed</li>
<li>reaktioner på injektionsstedet, såsom blå mærker, kløe og varme</li>
<li>kulderystelser</li>
</ul>
<p>Dette radiofarmaceutiske lægemiddel giver lave mængder ioniserende
stråling, hvilket er forbundet med den mindste risiko for kræft og
arvelige abnormiteter.</p>
<p>Indberetning af bivirkninger Hvis du oplever bivirkninger, bør du
tale med nuklearmedicineren. Dette gælder også mulige bivirkninger, som
ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også
indberette bivirkninger direkte til Lægemiddelstyrelsen via det
nationale rapporteringssystem anført i Appendiks V. Ved at indrapportere
bivirkninger kan du hjælpe med at fremskaffe mere information om
sikkerheden af dette lægemiddel.</p>
 </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du skal ikke selv opbevare dette lægemiddel. Opbevaring af lægemidlet
sker under ansvar af specialuddannet personale i særlige lokaler.
Opbevaring af radiofarmaceutiske lægemidler skal ske i overensstemmelse
med nationale bestemmelser om radioaktive materialer.</p>
<p>Oplysningerne nedenfor er kun beregnet til det specialuddannede
personale:</p>
<ul>
<li>Brug ikke Locametz efter den udløbsdato, der står på æsken og
etiketten efter EXP. Udløbsdatoen er den sidste dag i den nævnte
måned.</li>
<li>Opbevares ved temperaturer under 25 °C før rekonstitution.</li>
<li>Opbevares opretstående ved temperaturer under 30 °C efter
rekonstitution og radioaktiv mærkning. Anvendes inden for 6 timer.</li>
</ul>
 </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Locametz indeholder:</p>
<ul>
<li>Aktivt stof: gozetotid. Et hætteglas indeholder 25 mikrogram
gozetotid. Øvrige indholdsstoffer: gentisinsyre, natriumacetattrihydrat
og natriumchlorid (se "Locametz indeholder natrium" i punkt 2).</li>
</ul>
<p>Udseende og pakningsstørrelser Locametz er et
flerdosis-radiofarmaceutisk præparationssæt, der indeholder ét hætteglas
med hvidt frysetørret pulver (pulver til injektionsvæske,
opløsning).</p>
<p>Gallium-68 er ikke en del af sættet.</p>
<p>Efter rekonstitution og radioaktiv mærkning indeholder Locametz en
steril injektionsvæske, opløsning af gallium (68Ga) gozetotid med en
aktivitet på op til 1 369 MBq.</p>
<p>Efter rekonstitution indeholder gallium (68Ga) gozetotid
injektionsvæske, opløsning også saltsyre.</p>
<p>Pakningsstørrelse: 1 hætteglas.</p>
<p>Indehaver af markedsføringstilladelsen Novartis Europharm Limited
Vista Building Elm Park, Merrion Road Dublin 4 Irland</p>
<p>Fremstiller Advanced Accelerator Applications (Italy) S.R.L. Via
Crescentino snc 13040 Saluggia (VC) Italien</p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du
henvende dig til den lokale repræsentant for indehaveren af
markedsføringstilladelsen:</p>
<p>België/Belgique/Belgien Novartis Pharma N.V. Tél/Tel: +32 2 246
16<br />
Lietuva SAM Nordic Švedija Tel: +46 8 720 58<br />
България Novartis Bulgaria EOOD Тел: +359 2 489 98<br />
Luxembourg/Luxemburg Novartis Pharma N.V. Tél/Tel: +32 2 246 16<br />
Česká republika Novartis s.r.o. Tel: +420 225 775<br />
Magyarország Novartis Hungária Kft. Tel.: +36 1 457 65<br />
Danmark SAM Nordic Sverige Tlf.: +46 8 720 58<br />
Malta Novartis Pharma Services Inc. Tel: +356 2122 2 Deutschland
Novartis Pharma GmbH Tel: +49 911 273 0</p>
<p>Nederland Novartis Pharma B.V. Tel: +31 88 04 52<br />
Eesti SAM Nordic Rootsi Tel: +46 8 720 58<br />
Norge SAM Nordic Sverige Tlf: +46 8 720 58<br />
Ελλάδα ΒΙΟΚΟΣΜΟΣ ΑΕΒΕ Τηλ: +30 22920 63ή Novartis (Hellas) A.E.B.E. Τηλ:
+30 210 281 17<br />
Österreich Novartis Pharma GmbH Tel: +43 1 86 6 España Advanced
Accelerator Applications Ibérica, S.L.U. Tel: +34 97 6600<br />
Polska Advanced Accelerator Applications Polska Sp. z o.o. Tel.: +48 22
275 56<br />
France Advanced Accelerator Applications Tél: +33 1 55 47 63<br />
Portugal Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000
8 Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274<br />
România Novartis Pharma Services Romania SRL Tel: +40 21 31299<br />
Ireland Novartis Ireland Limited Tel: +353 1 260 12<br />
Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75<br />
Ísland SAM Nordic Svíþjóð Sími: +46 8 720 58<br />
Slovenská republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5 Italia
Novartis Farma S.p.A. Tel: +39 02 96 54 1</p>
<p>Suomi/Finland SAM Nordic Ruotsi/Sverige Puh/Tel: +46 8 720 58<br />
Κύπρος ΒΙΟΚΟΣΜΟΣ ΑΕΒΕ Τηλ: +30 22920 63ή Novartis Pharma Services Inc.
Τηλ: +357 22 690<br />
Sverige SAM Nordic Tel: +46 8 720 58<br />
Latvija SAM Nordic Zviedrija Tel: +46 8 720 58<br />
United Kingdom (Northern Ireland) Novartis Ireland Limited Tel: +44 1276
698</p>
<p>Denne indlægsseddel blev senest ændret</p>
<p>Andre informationskilder</p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det
Europæiske Lægemiddelagenturs hjemmeside <a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>.</p>
<hr />
<p>Nedenstående oplysninger er kun til sundhedspersoner:</p>
<p>Det fuldstændige produktresumé for Locametz er indlagt separat i
pakningen, så læger og sundhedspersoner kan få supplerende
videnskabelige og praktiske oplysninger om administration og anvendelse
af dette radiofarmaceutiske lægemiddel.</p>
<p>Se produktresuméet.</p>
 </div>"""      





                    
Instance: bundlepackageleaflet-en-6f21bde7c462d7396cfc7185d72d2377
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for locametz Package Leaflet for language en"
Description: "ePI document Bundle for locametz Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-6f21bde7c462d7396cfc7185d72d2377"
* entry[0].resource = composition-en-6f21bde7c462d7396cfc7185d72d2377

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp6f21bde7c462d7396cfc7185d72d2377"
* entry[=].resource = mp6f21bde7c462d7396cfc7185d72d2377
                            
                    
Instance: bundlepackageleaflet-da-6f21bde7c462d7396cfc7185d72d2377
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for locametz Package Leaflet for language da"
Description: "ePI document Bundle for locametz Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-6f21bde7c462d7396cfc7185d72d2377"
* entry[0].resource = composition-da-6f21bde7c462d7396cfc7185d72d2377

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp6f21bde7c462d7396cfc7185d72d2377"
* entry[=].resource = mp6f21bde7c462d7396cfc7185d72d2377
                            
                    



Instance: mp6f21bde7c462d7396cfc7185d72d2377
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Locametz 25 micrograms kit for radiopharmaceutical preparation"
Description: "Locametz 25 micrograms kit for radiopharmaceutical preparation"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/22/1692/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Locametz 25 micrograms kit for radiopharmaceutical preparation"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 6f21bde7c462d7396cfc7185d72d2377ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "locametz"

* status = #current
* mode = #working

* title = "List of all ePIs associated with locametz"

* subject = Reference(mp6f21bde7c462d7396cfc7185d72d2377)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#locametz "locametz"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-6f21bde7c462d7396cfc7185d72d2377) // locametz en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-6f21bde7c462d7396cfc7185d72d2377) // locametz da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-6f21bde7c462d7396cfc7185d72d2377
InstanceOf: List
Description: "ePI document List for locametz Package Leaflets"

* insert 6f21bde7c462d7396cfc7185d72d2377ListRuleset
    